© 2020 MJH Life Sciences and OncLive. All rights reserved.
© 2020 MJH Life Sciences™ and OncLive. All rights reserved.
September 25th 2020
Connie L. Batlevi, MD, PhD, discusses emerging therapies in follicular lymphoma.
Alan P. Z. Skarbnik, discusses ongoing research with PI3K inhibitors in follicular lymphoma.
John M. Burke, MD, discusses treatment options in relapsed/refractory follicular lymphoma.
Maha Hussain, MD, FACP, FASCO, discusses the importance of genomic profiling in metastatic castration-resistant prostate cancer.
Paul L. Nguyen, MD, discusses standard and investigational treatment options in high-risk prostate cancer.
Benjamin P. Levy, MD, discusses the disease-free survival benefit with adjuvant osimertinib in the phase 3 ADAURA trial.
Natalie I. U. Vokes, MD, discusses investigative biomarkers of response to checkpoint inhibitors in the field of oncology.
Arun Azad, PhD, discusses unmet needs for men with metastatic hormone-sensitive prostate cancer.
September 24th 2020
Andrew B. Nixon, PhD, MBA, discusses the role of microsatellite instability in cancer.
Petros Grivas, MD, PhD, discusses findings from the subgroup analyses of JAVELIN Bladder 100 in advanced urothelial cancer.